1. A need to update paradigms for myeloid cells within the tumor microenvironment to advance immunotherapy. Issue 1 (2022) Authors: Kinder, Michelle Journal: Immuno-oncology insights Issue: Volume 3:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody– drug conjugates and cancer immunotherapies. Issue 5 (2022) Authors: Dixit, Rakesh Journal: Immuno-oncology insights Issue: Volume 3:Issue 5(2022) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addressing the challenges of CRS in bispecific monoclonal antibody cancer therapy. Issue 6 (2022) Authors: Vaze, Anjali; Kuebler, Peter Journal: Immuno-oncology insights Issue: Volume 3:Issue 6(2022) Page Start: 315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Addressing the complexity of the TME with organoids. Issue 1 (2023) Authors: McGuigan, Roisin; Braekeleer, Etienne De Journal: Immuno-oncology insights Issue: Volume 4:Issue 1(2023) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Analyzing current trends and future directions in I-O clinical development. Issue 1 (2020) Authors: GRAYBOSCH, DAINA Journal: Immuno-oncology insights Issue: Volume 1:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Antibody drug conjugates accelerated approvals targeting oncology. Issue 6 (2021) Authors: Jamieson, Stuart; Myatt, Daniel; Liddell, John Journal: Immuno-oncology insights Issue: Volume 2:Issue 6(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Antigen-presenting dendritic cells as targets for cancer immunotherapy. Issue 1 (2021) Authors: Munn, David H; , Rafal Pacholczyk; Sharma, Madhav D Journal: Immuno-oncology insights Issue: Volume 2:Issue 1(2021) Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Assessing efficacy & MoA of mono & combo immunotherapies in preclinical humanized models. Issue 1 (2023) Authors: Thiam, Kader; Surya, Arjun; Horst, Edward van der Journal: Immuno-oncology insights Issue: Volume 4:Issue 1(2023) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. BCMA targeting CAR T cells using a novel D-domain binder for multiple myeloma: clinical development update. Issue 1 (2022) Authors: Rotte, Anand; Heery, Christopher; Gliner, Bradford; Tice, David; Hilbert, David M Journal: Immuno-oncology insights Issue: Volume 3:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Better by design: a regulatory perspective on rationalizing combination selection and development. Issue 5 (2022) Authors: McGuigan, Roisin Journal: Immuno-oncology insights Issue: Volume 3:Issue 5(2022) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗